GPS News  
Large-Scale Trial Of HIV Vaccine Launched In South Africa

AIDS ignorance rampant in pandemic-hit Malawi: survey
Blantyre (AFP) Feb 09 - About 60 percent of people aged between 15 and 49 in AIDS-ravaged Malawi lack comprehensive knowledge about HIV prevention, a new survey has said. A UN-funded study of 31,200 households across the impoverished southern African nation unveiled Thursday showed that only 40 percent of the targeted respondents were properly clued in about the disease and prevention methods. "The indicators make depressing reading," said Health Minister Marjorie Ngaunje.

"However there are still some positive indicators in the survey that reflect the programmes and policies the current government put in place to address the plight of women and children in the country." The study said that 40 percent of women aged between 15 and 24 used a condom while having sex with a casual partner. The figure for men was significantly higher at 60 percent. Around 14 percent of Malawi's 13 million people are infected with HIV, according to official figures. There are about 78,000 AIDS-related deaths every year.

by Staff Writers
Washington (AFP) Feb 08, 2007
South Africa has launched Africa's largest-yet clinical trial of a promising vaccine against HIV, the virus which causes AIDS, the US National Institutes of Health announced Thursday. About 3,000 men and women who do not have HIV will be enrolled in the program to test the vaccine, supplied by drugmaker Merck and Co., which in earlier, smaller trials proved effective in more than half the people who received it.

"Our best hope of ending the AIDS epidemic is a safe and effective vaccine," said NIH director Elias Zerhouni in a statement.

"To achieve that goal requires the concerted effort of governments, scientists and private industry as well as participation by well-informed volunteers."

The trial is being undertaken by the South African AIDS Vaccine Initiative (SAAVI) and the HIV Vaccine Trials Network (HVTN), together with NIH's National Institute of Allergy and Infectious Diseases.

The NIH said the trial is in the phase II "test of concept" phase for the vaccine, designed to generate preliminary information on the efficacy of the vaccine before deciding on a larger phase III trial which, if successful, could lead to licensing and mass production of the vaccine.

The trial will involve volunteer men and women between 18 and 35, with some receiving the test vaccine and others a placebo, to determine whether the vaccine can prevent HIV from infecting someone or if it can suppress the level of HIV early on in those who do become infected.

NIH said that the vaccine contains copies of only three key HIV genes, and not the entire HIV virus, so that those receiving it will not be infected with HIV.

The vaccine has already been tested on some 1,800 people, and since two years ago a separate trial has been ongoing in the United States, Canada, South America, the Caribbean and Australia.

Source: Agence France-Presse

Related Links
US National Institutes of Health
The science and news of Epidemics on Earth
Epidemics on Earth - Bird Flu, HIV/AIDS, Ebola



Memory Foam Mattress Review
Newsletters :: SpaceDaily :: SpaceWar :: TerraDaily :: Energy Daily
XML Feeds :: Space News :: Earth News :: War News :: Solar Energy News


AIDS Vaccine Closer But Remains Elusive
Washington (UPI) Feb 08, 2007
The launch of the first large-scale AIDS vaccine trial could bring the world one step closer to the elusive goal of preventing the disease's spread, researchers say, but there is still a long road to a marketable vaccine. The trial is "part of a complex and multi-faceted strategy," said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, which is partially funding the research.







  • Anger As Britons Face Air Tax Hike
  • Bats In Flight Reveal Unexpected Aerodynamics
  • Lockheed Martin And Boeing Form Strategic Alliance To Promote Next-Gen Air Transportation System
  • Time to test the Guardian Missile Defense System For Commercial Aircraft

  • EU proposes 25 percent cut in new car emissions
  • EU Reaches Compromise On New Car Emissions Plan
  • London Council Votes For Emissions-Related Parking Charges
  • Multimedia Car Radio Of The Future

  • Interim Polar System Reaches Full Operational Capability
  • Raytheon Demonstrates Satellite Communications Alternative
  • Northrop Grumman Delivers Payload For First Advanced EHF Military Communications Satellite
  • Defense Support Program Flight 23 Sees Integration Of Satellite And Launch Vehicle Payload Adapter

  • Deployment Of US Missile Defense Could Trigger New Arms Race
  • Israel Stresses Anti-Missile Test Message To Iran
  • Russia Protests US Missile Shield But Vows To Avoid Arms Race
  • Congressional Research Service Skepticism On BMD Grows

  • Doomsday Vault Will Protect Millions Of Seeds
  • Canadian Farmer On Global Crusade Against GM Seeds
  • New Management Tool For East Australian Graziers
  • Ancient Genes Used To Produce Salt-Tolerant Wheat

  • Health Problems Hit Indonesia Flood Victims
  • Japan Launches Alert System For Tsunamis And Missiles
  • Call To Move Indonesian Capital After Deadly Floods
  • Catastrophe Bonds A Market Answer To Hail Or High Water

  • In Tiny Supercooled Clouds Physicists Exchange Light And Matter
  • Liquid Crystals Stabilised
  • Ultra-Dense Optical Storage On One Photon
  • Nanocomposite Research Yields Strong And Stretchy Fibers

  • Robotic Exoskeleton Replaces Muscle Work
  • Robotic Arm Aids Stroke Victims
  • Scientists Study Adhesive Capabilities Of Geckos To Develop Surveillance Or Inspection Robots
  • Japanese Women To Try Lipstick With Touch Of Button

  • The content herein, unless otherwise known to be public domain, are Copyright Space.TV Corporation. AFP and UPI Wire Stories are copyright Agence France-Presse and United Press International. ESA Portal Reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space.TV Corp on any Web page published or hosted by Space.TV Corp. Privacy Statement